Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Ono Scores 12.5% Rise in Q1 Revenue on Opdivo, Forxiga
August 1, 2023
- Shionogi Logs Record Earnings Q1 on Xocova, ADHD License Transfer
August 1, 2023
- Daiichi Sankyo Enjoys Rosy Q1 Earnings on Strong Mainstays
August 1, 2023
- Sumitomo’s Group Sales Halve in Q1 as Latuda LOE in US Takes Toll
August 1, 2023
- Otsuka’s Pharma H1 Sales Zoom 20% as Global Brands Fare Well
August 1, 2023
- Mitsubishi Tanabe Rolls Out Tardive Dyskinesia Drug in Thailand
August 1, 2023
- Zeria’s Swiss Unit Launches JV in US to Develop Oral mAb for Ulcerative Colitis
July 31, 2023
- Novo Seeks Label Expansion of Concizumab for Hemophilia without Inhibitors
July 31, 2023
- UCB Submits Anti-Epileptic Drug Brivaracetam in Japan
July 31, 2023
- Nippon Shinyaku’s DMD Drug Nabs Breakthrough Therapy Designation
July 31, 2023
- Chugai Marks 2-Digit Growth in Core Earnings in H1 on Robust Sales, Exports
July 28, 2023
- Takeda Set to Bring Entyvio Back to Double-Digit Growth in FY2023: Exec
July 28, 2023
- Takeda Q1 Sales Up 8.9%, Led by Key Product Growth and Weak Yen
July 28, 2023
- Pfizer Seeks Pediatric ALL Nod for Besponsa in Japan
July 28, 2023
- AbbVie’s Parkinson’s Drug Vyalev Now Available in Japan
July 27, 2023
- Ono Settles I/O Patent Row with AstraZeneca, Wins US$140 Million
July 26, 2023
- Otsuka Ups H1 Earnings Guidance on Bullish Global Products
July 26, 2023
- Astellas, PeptiDream to Pair Up to Discover Novel Protein Degraders
July 26, 2023
- Trodelvy Launch on Horizon, Gilead Japan to Hire Oncology Reps from Early 2024
July 26, 2023
- After CAR-T Transfer, Gilead Sets Cell Therapy as Key Biz Pillar for Growth in Japan
July 26, 2023
ページ
Chugai Pharmaceutical’s Duchenne muscular dystrophy (DMD) gene therapy Elevidys has finally reached the Japanese market after months of safety reviews…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…